Chief Executive Officer and Chairman, Embecta
Appears in 1 story
Leading Embecta's post-spinoff transformation strategy
Embecta, a diabetes injection device company that Becton Dickinson spun off in 2022, announced its first major acquisition: Owen Mumford, a 74-year-old British medical device maker, for up to £150 million. The deal gives Embecta access to Owen Mumford's Aidaptus auto-injector platform and pivots the company from making insulin syringes into the booming market for injectable drug delivery devices used in obesity treatments, autoimmune therapies, and emergency anaphylaxis care.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
